Corcept Therapeutics Incorporated - Common Stock (CORT)
34.95
-3.25 (-8.51%)
NASDAQ · Last Trade: Jan 6th, 3:46 AM EST
Detailed Quote
Previous Close
38.20
Open
38.14
Bid
34.92
Ask
34.94
Day's Range
34.89 - 38.17
52 Week Range
32.99 - 117.33
Volume
5,194,686
Market Cap
4.05B
PE Ratio (TTM)
40.17
EPS (TTM)
0.9
Dividend & Yield
N/A (N/A)
1 Month Average Volume
2,680,096
Chart
About Corcept Therapeutics Incorporated - Common Stock (CORT)
Corcept Therapeutics is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative treatments for patients with severe metabolic and psychiatric disorders. The company primarily specializes in the modulation of glucocorticoid signaling, a pathway that plays a key role in various diseases, particularly those characterized by chronic stress and inflammation. Corcept's lead product is designed to help patients suffering from conditions such as Cushing's syndrome, and the company is also engaged in research aimed at expanding its therapeutic applications to broader health issues. Through its dedication to advancing scientific understanding and developing effective therapies, Corcept aims to improve the quality of life for patients battling these challenging health conditions. Read More
Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT)
fell 4.5% in the morning session after the company’s stock faced continued selling pressure following the U.S. Food and Drug Administration's (FDA) rejection of its new drug application for relacorilant.
NEW YORK, NY - January 5, 2026 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (NASDAQ: CORT).
NEW YORK, NY - January 3, 2026 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (NASDAQ: CORT).
NEW YORK, NY - January 2, 2026 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (NASDAQ: CORT).
NEW YORK, NY - January 1, 2026 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (NASDAQ: CORT).
Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT)
fell 51.4% in the afternoon session after the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) rejecting the company's New Drug Application for relacorilant.
NEW YORK, NY - December 31, 2025 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (NASDAQ: CORT).
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the U.S. Food and Drug Administration (FDA or the Agency) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT)
fell 4.7% in the afternoon session after investor anxiety mounted ahead of a key U.S. Food and Drug Administration (FDA) decision for its drug candidate, relacorilant.
Corcept has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 13.8% to $81.75 per share while the index has gained 13.9%.
